Liposomal Subunit Vaccine Development Service

Introduction to Our Liposomal Subunit Vaccine Development Service

BOC Sciences offers advanced liposomal subunit vaccine development through the combined use of nanotechnology and immunological knowledge to produce highly effective and safe vaccines. We provide liposome-based antigen delivery alongside formulation optimization and comprehensive analytical validation to achieve both robust immune response and long-term stability in our services. Our incorporation of specialized lipid-based carriers improves antigen delivery and adjuvanticity while increasing cellular uptake which results in enhanced vaccine performance.

How to Get Started?

Reach out for a personalized consultation during which we will evaluate your antigen requirements and vaccine objectives to design a specific liposomal vaccine formulation and development plan according to your project needs.

Inquire today to accelerate your liposomal subunit vaccine development program.

Request A Quote

Contact us to discuss how we can help you achieve your research goals

Price Inquiry

Why Use Liposomes in Subunit Vaccines Development?

Liposomal delivery systems provide an effective and safe method for subunit vaccines which solves major issues including inadequate immunogenicity as well as fast antigen elimination and unstable formulations. Liposomal subunit vaccines deliver superior outcomes through tailored lipid compositions and adjuvant systems which result in higher efficacy and improved safety profiles while enabling scalable production potential positioning them as the optimal platform for future vaccines.

  • Reduction of Storage and Transport Costs

Subunit vaccines depend on purified antigen components that frequently face enzymatic breakdown and quick elimination from the body. Liposomes protect antigens by shielding them from proteolytic degradation while also lengthening their circulation half-life. The protective mechanism maintains antigen stability to prolong effective immune activation.

  • Improved Immunogenicity Through Controlled Antigen Release

Unlike soluble antigens that are quickly eliminated, liposomal formulations enable sustained antigen release, allowing for prolonged immune system exposure. This controlled delivery mimics natural infection patterns, resulting in stronger and longer-lasting immune responses.

  • Targeted Delivery to Antigen-Presenting Cells (APCs)

Liposomes can be engineered to target specific immune cells, such as dendritic cells and macrophages, which are crucial for antigen presentation. By directing antigens to these professional APCs, liposomes enhance MHC class I and II presentation, leading to both humoral and cellular immune responses.

Our Liposomal Subunit Vaccine Development Service

BOC Sciences provides a comprehensive liposomal subunit vaccine development service, focusing on liposome-based antigen delivery, formulation engineering, and immunogenicity enhancement. Our approach integrates advanced lipid nanotechnology with immunological expertise to create stable, highly effective subunit vaccines. We offer custom lipid-based vaccine formulations that optimize antigen presentation, enhance immune response, and ensure superior bioavailability.

Antigen Selection and Optimization

The first step in developing a successful liposomal subunit vaccine is the careful selection and optimization of the antigen. At BOC Sciences, we work with recombinant proteins, synthetic peptides, and virus-like particles (VLPs) to identify the most effective antigenic components that will trigger a robust immune response.

  • Recombinant Proteins – We express and purify viral, bacterial, or tumor antigens in suitable systems (e.g., bacterial, yeast, mammalian cells).
  • Peptide-based Antigens – We design epitope-focused peptides that target specific T-cell and B-cell epitopes for enhanced specificity.
  • Virus-like Particles – For certain applications, we use VLPs that mimic the virus structure to induce a strong immune response while avoiding the risk of infection.

Custom Liposomal Antigen Encapsulation

Our expertise in liposomal formulation ensures that the lipid composition of your subunit vaccine is optimized for the specific type of antigen you are working with. Examples of how we tailor liposome formulations include:

  • Phosphatidylcholine (PC)-Cholesterol Liposomes: This combination is often used for recombinant protein-based vaccines, as PC offers excellent biocompatibility and cholesterol enhances membrane stability, which is crucial for maintaining antigen integrity in liposomal subunit vaccines.
  • Cationic Liposomes: These are designed to enhance antigen delivery to antigen-presenting cells (APCs) such as dendritic cells and macrophages. The positively charged surface interacts favorably with the negatively charged cell membranes, facilitating efficient cellular uptake and improved immune activation.
  • PEGylated Liposomes: We also use PEGylated liposomes to increase circulation time in the bloodstream, reducing premature clearance by the immune system. This is especially beneficial for vaccines designed to be delivered in lower doses over extended periods.

Liposomal Adjuvants and Immune Enhancement

To further enhance the immune response, we integrate various adjuvants directly into the liposomal structure. This co-delivery approach ensures that both the antigen and the adjuvant are delivered efficiently to the immune system, boosting antigen presentation and immune activation. Examples include:

  • CpG Oligodeoxynucleotides (ODNs): CpG motifs activate toll-like receptors (TLRs) on dendritic cells, promoting strong Th1 responses. We encapsulate CpG ODNs within the liposomes to ensure efficient co-delivery with the antigen, enhancing the immune response.
  • Monophosphoryl Lipid A (MPLA): This adjuvant promotes a strong immune response while minimizing inflammation, making it particularly useful in liposomal subunit vaccines for infectious diseases or autoimmune disorders.
  • Saponin-Based Adjuvants: Saponins, like QS-21, are used in liposomes to create lipid rafts within the immune cell membranes, enhancing antigen uptake and activation of innate immunity.

And once the liposomal subunit vaccine formulation is complete, we conduct in vitro and in vivo testing to evaluate its immunogenicity.

Optimal Workflow of Liposomal Subunit Vaccine Development Service

Our structured development workflow ensures high-quality and reproducible subunit vaccine formulations:

1. Initial Consultation and Design

The process begins with a comprehensive consultation to understand your specific needs, including the target antigen and the desired immune response. We assess key factors like:

  • Antigen type (e.g., recombinant proteins, peptides)
  • Vaccine application (e.g., infectious disease, cancer immunotherapy)
  • Adjuvant selection for immune enhancement
  • Liposome formulation preferences (e.g., cationic, PEGylated)

2. Liposomal Formulation Development

We proceed to design and optimize the liposomal formulation tailored to your antigen. This involves selecting the appropriate lipids, adjuvants, and stabilizers to ensure:

  • Efficient encapsulation of the antigen
  • Long-term stability and protection of the antigen
  • Enhanced immune system recognition and uptake

3. Antigen Loading and Optimization

Once the liposomal formulation is developed, the next step involves loading the selected antigen (protein, peptide, or other antigens) into the liposomes.

4. Advanced Liposomal Characterization and Stability Measurement

We assess the liposome size, encapsulation efficiency, and release kinetics using methods like dynamic light scattering (DLS) and transmission electron microscopy (TEM). These analyses ensure the stability and efficacy of the liposomal formulation.

5. Preclinical Immunogenicity Testing

Once the formulation is optimized, we proceed with immunogenicity testing in animal models to assess:

  • Humoral immune response (antibody production)
  • Cell-mediated immunity (T-cell activation)
  • Safety profile, ensuring the vaccine is non-toxic and well-tolerated

We use adjuvant integration and evaluate immune response profiles to confirm the vaccine's potential for both short-term and long-term protection.

6. Scale-Up and cGMP Manufacturing

Following successful preclinical trials, we initiate scale-up production for clinical trial applications, offering cGMP-compliant manufacturing to meet regulatory standards.

  • Batch-to-batch consistency
  • Quality control throughout the production process

Why Choose Our Liposomal Subunit Vaccine Development Service?

Applications of Our Liposomal Subunit Vaccine Development Service

Our Liposomal Subunit Vaccine Development Service enables the precise design and formulation of liposome-based vaccines, ensuring enhanced antigen stability, targeted delivery, and controlled immune response. Key applications include:

FAQs - Insights Liposomal Subunit Vaccine Development

Product

What makes liposomal subunit vaccines more effective than traditional vaccines?

Liposomal subunit vaccines provide a targeted delivery system that improves the bioavailability of antigens and enhances immune system recognition.

How does liposomal vaccine delivery compare to lipid nanoparticles (LNPs)?

Liposomal vaccines primarily deliver protein and peptide antigens, while LNPs are optimized for mRNA/DNA vaccine delivery. Both use lipid-based carriers, but their design and application differ based on the therapeutic approach.

Can liposomes be designed for targeted immune responses (e.g., mucosal vaccines)?

Yes, we can engineer liposomal vaccines for mucosal delivery (e.g., intranasal or oral routes) by modifying lipid composition to enhance mucosal uptake and immune stimulation.

What are the biggest challenges in liposomal vaccine development, and how do you address them?

Some common challenges include:

  • Low antigen encapsulation efficiency - Optimized lipid composition and encapsulation techniques ensure high antigen retention.
  • Liposomal instability - We conduct stability studies and apply PEGylation or lyophilization for enhanced shelf life.
  • Batch-to-batch variability - cGMP-compliant processes ensure consistent formulation and scalable production.

BOC Sciences offers an unparalleled liposomal subunit vaccine development service, combining innovative liposome formulations with a thorough understanding of immunology and nanotechnology. Whether you are looking to develop a vaccine for infectious diseases, cancer immunotherapy, or autoimmune treatments, our liposomal subunit vaccine service is equipped to support your project from concept through to clinical trial readiness. Contact us today to discuss your liposomal subunit vaccine development projects.

Supplementary Knowledge

What is a Subunit Vaccine?

Subunit vaccines consist of specific purified antigenic parts from pathogens instead of using entire microorganisms. Scientists choose specific components including proteins, peptides, polysaccharides and recombinant antigens to incite protective immune responses with minimal side effects. Here are some types of subunit vaccines:

  • Protein Subunit Vaccines – Utilize isolated viral or bacterial proteins (e.g., Hepatitis B vaccine).
  • Peptide-Based Vaccines – Comprise synthetic peptide sequences that mimic pathogen epitopes.
  • Polysaccharide and Conjugate Vaccines – Target bacterial surface polysaccharides, often conjugated with carrier proteins for enhanced immunogenicity (e.g., meningococcal vaccines).
  • Virus-Like Particle (VLP) Vaccines – Non-infectious structures resembling viruses that present antigens in their native conformation (e.g., HPV vaccine).

Your Liposome CDMO Partner, Empowering Innovative Drug Development.

Contact Us

USA
  • International :
    US & Canada (Toll free):
  • Fax:
  • Email:

Europe

  • Tel:
  • Email:

Products

Solutions

Copyright ©  2025  BOC Sciences. All rights reserved.

Inquiry Basket
Loading ......
Delete selected Go to checkout